Literature DB >> 12473553

Lifetime risk for developing congestive heart failure: the Framingham Heart Study.

Donald M Lloyd-Jones1, Martin G Larson, Eric P Leip, Alexa Beiser, Ralph B D'Agostino, William B Kannel, Joanne M Murabito, Ramachandran S Vasan, Emelia J Benjamin, Daniel Levy.   

Abstract

BACKGROUND: Congestive heart failure (CHF) is an increasing public health problem. METHODS AND
RESULTS: Among Framingham Heart Study subjects who were free of CHF at baseline, we determined the lifetime risk for developing overt CHF at selected index ages. We followed 3757 men and 4472 women from 1971 to 1996 for 124 262 person-years; 583 subjects developed CHF and 2002 died without prior CHF. At age 40 years, the lifetime risk for CHF was 21.0% (95% CI 18.7% to 23.2%) for men and 20.3% (95% CI 18.2% to 22.5%) for women. Remaining lifetime risk did not change with advancing index age because of rapidly increasing CHF incidence rates. At age 80 years, the lifetime risk was 20.2% (95% CI 16.1% to 24.2%) for men and 19.3% (95% CI 16.5% to 22.2%) for women. Lifetime risk for CHF doubled for subjects with blood pressure >/=160/100 versus <140/90 mm Hg. In a secondary analysis, we only considered those who developed CHF without an antecedent myocardial infarction; at age 40 years, the lifetime risk for CHF was 11.4% (95% CI 9.6% to 13.2%) for men and 15.4% (95% CI 13.5% to 17.3%) for women.
CONCLUSIONS: When established clinical criteria are used to define overt CHF, the lifetime risk for CHF is 1 in 5 for both men and women. For CHF occurring in the absence of myocardial infarction, the lifetime risk is 1 in 9 for men and 1 in 6 for women, which highlights the risk of CHF that is largely attributable to hypertension. These results should assist in predicting the population burden of CHF and placing greater emphasis on prevention of CHF through hypertension control and prevention of myocardial infarction.

Entities:  

Mesh:

Year:  2002        PMID: 12473553     DOI: 10.1161/01.cir.0000039105.49749.6f

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  419 in total

1.  Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling.

Authors:  Qinghang Liu; Yi Chen; Mannix Auger-Messier; Jeffery D Molkentin
Journal:  Circ Res       Date:  2012-03-08       Impact factor: 17.367

2.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

Review 3.  A systematic review of validated methods for identifying heart failure using administrative data.

Authors:  Jane S Saczynski; Susan E Andrade; Leslie R Harrold; Jennifer Tjia; Sarah L Cutrona; Katherine S Dodd; Robert J Goldberg; Jerry H Gurwitz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01       Impact factor: 2.890

Review 4.  STEMI and heart failure in the elderly: role of adverse remodeling.

Authors:  Anwar Jelani; Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2010-09       Impact factor: 4.214

Review 5.  Translating genetic discoveries to improvements in cardiovascular care: the path to personalized medicine.

Authors:  Jennifer L Hall
Journal:  J Cardiovasc Transl Res       Date:  2008-02-08       Impact factor: 4.132

6.  Country of birth and risk of hospitalization due to heart failure: a Swedish population-based cohort study.

Authors:  Yan Borné; Gunnar Engström; Birgitta Essén; Jan Sundquist; Bo Hedblad
Journal:  Eur J Epidemiol       Date:  2010-12-24       Impact factor: 8.082

7.  Prediction of cardiovascular disease among hematopoietic cell transplantation survivors.

Authors:  Saro H Armenian; Dongyun Yang; Jennifer Berano Teh; Liezl C Atencio; Alicia Gonzales; F Lennie Wong; Wendy M Leisenring; Stephen J Forman; Ryotaro Nakamura; Eric J Chow
Journal:  Blood Adv       Date:  2018-07-24

Review 8.  Getting to the Heart of Alzheimer Disease.

Authors:  Joshua M Tublin; Jeremy M Adelstein; Federica Del Monte; Colin K Combs; Loren E Wold
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

Review 9.  Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?

Authors:  Hashim Khan; Marco Metra; John E A Blair; Mark Vogel; Matthew E Harinstein; Gerasimos S Filippatos; Hani N Sabbah; Herve Porchet; Giovanni Valentini; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2009-02-24       Impact factor: 4.214

10.  Case management program for patients with chronic heart failure: effectiveness in terms of mortality, hospital admissions and costs.

Authors:  Verena Hendricks; Simone Schmidt; Achim Vogt; Detlef Gysan; Volker Latz; Ines Schwang; Reinhard Griebenow; Rainer Riedel
Journal:  Dtsch Arztebl Int       Date:  2014-04-11       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.